Claims for Patent: 7,547,435

Summary for Patent: 7,547,435

Title:	Pharmacological vitreolysis
Abstract:	Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
Inventor(s):	Pakola; Steve (Sleepy Hollow, NY), De Smet; Marc (Amstelveen, NL)
Assignee:	ThromboGenics NV (Leuven, BE)
Application Number:	10/729,475
Patent Claims:	1. A method of liquefying a vitreous and/or inducing posterior vitreous detachment of an eye of a subject, comprising contacting the vitreous and/or an aqueous humor in the eye of the subject with an effective amount of a composition comprising microplasmin, wherein the method results in liquefying a vitreous and/or inducing posterior vitreous detachment of the eye of a subject. 2. The method of claim 1, wherein said microplasmin is selected from the group consisting of recombinant microplasmin, stabilized microplasmin, and stabilized, recombinant microplasmin. 3. The method of claim 1, wherein the composition is a liquid solution, and wherein the step of contacting the vitreous and/or the aqueous humor with the composition comprises injecting the liquid solution into the vitreous and/or the aqueous humor. 4. The method of claim 1, wherein the subject is a human. 5. The method of claim 1, wherein the method is used for treating a subject having, a vitreoretinal disease or disorder. 6. The method of claim 1, wherein the method is performed in the absence of non-pharmacological vitrectomy. 7. The method of claim 1, wherein the method is performed as an adjunct to vitrectomy. 8. The method of claim 1, wherein an effective amount of microplasmin is in the range of 0.005 mg to 0.2 mg per eye. 9. A method of treating a vitreoretinal disease or disorder, or a complication of a vitreoretinal disease or disorder, of an eye of a subject, comprising contacting a vitreous and/or an aqueous humor in the eye of the subject with an effective amount of a composition comprising microplasmin, wherein the method results in vitreous liquefaction and/or posterior vitreous detachment in the eye of the subject, thereby treating the vitreoretinal disease or disorder, or the complication of the vitreoretinal disease or disorder, of the eye of the subject. 10. The method of claim 9, wherein said microplasmin is selected from the group consisting of recombinant microplasmin, stabilized microplasmin, and stabilized, recombinant microplasmin. 11. The method of claim 9, wherein the composition is a liquid solution, and wherein the step of contacting the vitreous and/or the aqueous humor with the composition comprises injecting the liquid solution into the vitreous and/or the aqueous humor. 12. The method of claim 9, wherein the subject is a human. 13. The method of claim 9, wherein the method is performed in the absence of non-pharmacological vitrectomy. 14. The method of claim 9, wherein the method is performed as an adjunct to vitrectomy. 15. The method of claim 9, wherein an effective amount of microplasmin is in the range of 0.005 mg to 0.2 mg per eye. 16. A method of performing a vitrectomy in a subject, comprising contacting a vitreous and/or aqueous humor of an eye of the subject with an effective amount of a composition comprising microplasmin, prior to or at the same time as the removal of the vitreous. 17. The method of claim 16, wherein said microplasmin is selected from the group consisting of recombinant microplasmin, stabilized microplasmin, and stabilized, recombinant microplasmin. 18. The method of claim 16, wherein the composition is a liquid solution, and wherein the step of contacting the vitreous and/or the aqueous humor with the composition comprises injecting the liquid solution into the vitreous and/or the aqueous humor. 19. The method of claim 16, wherein the subject is a human. 20. The method of claim 16, wherein an effective amount of microplasmin is in the range of 0.005 mg to 0.2 mg per eye. 21. The method of claim 4, wherein the human subject is administered human microplasmin. 22. The method of claim 12, wherein the human subject is administered human microplasmin. 23. The method of claim 19, wherein the human subject is administered human microplasmin.

Details for Patent 7,547,435

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422	02/22/2017		2022-12-06
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422	10/17/2012		2022-12-06

International Patent Family for US Patent 7,547,435

Country	Patent Number	Estimated Expiration
South Africa	200505193
World Intellectual Property Organization (WIPO)	2004052228
United States of America	9770494
United States of America	9186394
United States of America	8834869
United States of America	8747842